Top

Archives of Gynecology and Obstetrics

Published in:

Open Access 01-12-2018 | Gynecologic Oncology

Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin

Authors: Dominik Bieg, Daniel Sypniewski, Ewa Nowak, Ilona Bednarek

Published in: Archives of Gynecology and Obstetrics | Issue 6/2018

Abstract

Purpose

This study aimed at evaluating whether morin (a natural flavonoid and a known inhibitor of NF-κB) can sensitize ovarian cancer cells to cisplatin by decreasing the expression of galectin-3, which is an anti-apoptotic protein regulated by NF-κB transcription factor.

Methods

To assess the possibility of augmentation the activity of cisplatin by morin, we studied the separate and the combined effect of morin and cisplatin on viability, proliferation, and apoptosis of TOV-21G (cisplatin-sensitive) and SK-OV-3 (cisplatin-resistant) ovarian cancer cells. We also analysed the effect of morin and cisplatin on galectin-3 expression at the mRNA and protein levels.

Results

We demonstrated that morin possess antitumor activity against TOV-21G and SK-OV-3 ovarian cancer cells by reducing cell viability and proliferation as well as increasing the induction of apoptosis. Co-treatment of the cells with selected concentrations of morin and cisplatin, accordingly to specific treatment approaches, reveals a synergism, which leads to sensitization of the cells to cisplatin. During this sensitization, morin significantly reduces the expression of galectin-3 at the mRNA and protein level, regardless of the presence of cisplatin.

Conclusions

Morin sensitizes TOV-21G and SK-OV-3 ovarian cancer cells to cisplatin, what is associated with a decrease of the expression of galectin-3.

Arzuman L, Beale P, Chan C et al (2014) Synergism from combinations of tris (benzimidazole) monochloroplatinum(II) chloride with capsaicin, quercetin, curcumin and cisplatin in human ovarian cancer cell lines. Anticancer Res 34:5453–5464PubMed

Long Q, Xie Y, Huang Y et al (2013) Induction of apoptosis and inhibition of angiogenesis by PEGylated liposomal quercetin in both cisplatin-sensitive and cisplatin-resistant ovarian cancers. J Biomed Nanotechnol 9:965–975. https://doi.org/10.1166/jbn.2013.1596 CrossRefPubMed

Yang Z, Liu Y, Liao J et al (2015) Quercetin induces endoplasmic reticulum stress to enhance cDDP cytotoxicity in ovarian cancer: involvement of STAT3 signaling. FEBS J 282:1111–1125. https://doi.org/10.1111/febs.13206 CrossRefPubMed

Zhu X, Ji M, Han Y et al (2017) PGRMC1-dependent autophagy by hyperoside induces apoptosis and sensitizes ovarian cancer cells to cisplatin treatment. Int J Oncol 50:835–846. https://doi.org/10.3892/ijo.2017.3873 CrossRefPubMed

Kang HG, Kim S, Cho Y et al (2016) Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain. Oncotarget 7:68229–68241PubMedPubMedCentral

Koukoura O, Spandidos DA, Daponte A, Sifakis S (2014) DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (review). Mol Med Rep 10:3–9. https://doi.org/10.3892/mmr.2014.2221 CrossRefPubMedPubMedCentral

Wei Z, He X, Kou J et al (2015) Renoprotective mechanisms of morin in cisplatin-induced kidney injury. Int Immunopharmacol 28:500–506. https://doi.org/10.1016/j.intimp.2015.07.009 CrossRefPubMed

Davis A, Tinker A, Friedlander M (2014) “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol 133:624–631. https://doi.org/10.1016/j.ygyno.2014.02.038 CrossRefPubMed

Galluzzi L, Vitale I, Michels J et al (2014) Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 5:e1257. https://doi.org/10.1038/cddis.2013.428 CrossRefPubMedPubMedCentral

10.

Oiso S, Ikeda R, Nakamura K et al (2012) Involvement of NF-κB activation in the cisplatin resistance of human epidermoid carcinoma KCP-4 cells. Oncol Rep 28:27–32. https://doi.org/10.3892/or.2012.1801 CrossRefPubMed

11.

Ataie-Kachoie P, Badar S, Morris DL, Pourgholami MH (2013) Minocycline targets the NF-κB nexus through suppression of TGF-β1-TAK1-IκB signaling in ovarian cancer. Mol Cancer Res 11:1279–1291. https://doi.org/10.1158/1541-7786.MCR-13-0239 CrossRefPubMed

12.

Mabuchi S, Ohmichi M, Nishio Y et al (2004) Inhibition of NFκB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 279:23477–23485. https://doi.org/10.1074/jbc.M313709200 CrossRefPubMed

13.

Wang L, Guo X-L (2016) Molecular regulation of galectin-3 expression and therapeutic implication in cancer progression. Biomed Pharmacother 78:165–171. https://doi.org/10.1016/j.biopha.2016.01.014 CrossRefPubMed

14.

Bin Park G, Kim DJ, Kim YS et al (2015) Silencing of galectin-3 represses osteosarcoma cell migration and invasion through inhibition of FAK/Src/Lyn activation and β-catenin expression and increases susceptibility to chemotherapeutic agents. Int J Oncol 46:185–194. https://doi.org/10.3892/ijo.2014.2721 CrossRef

15.

Oishi T, Itamochi H, Kigawa J et al (2007) Galectin-3 may contribute to cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer 17:1040–1046. https://doi.org/10.1111/j.1525-1438.2007.00916.x CrossRefPubMed

16.

Kobayashi T, Shimura T, Yajima T et al (2011) Transient silencing of galectin-3 expression promotes both in vitro and in vivo drug-induced apoptosis of human pancreatic carcinoma cells. Clin Exp Metastasis 28:367–376. https://doi.org/10.1007/s10585-011-9376-x CrossRefPubMed

17.

Pokrywka M, Bubka M, Janik M et al (2016) Gal-3 does not suppress cisplatin-induced apoptosis in A-375 melanoma cells. Cell Biol Int 40:428–438. https://doi.org/10.1002/cbin.10582 CrossRefPubMed

18.

Wongkham S, Junking M, Wongkham C et al (2009) Suppression of galectin-3 expression enhances apoptosis and chemosensitivity in liver fluke-associated cholangiocarcinoma. Cancer Sci 100:2077–2084. https://doi.org/10.1111/j.1349-7006.2009.01304.x CrossRefPubMed

19.

Venu Gopal J (2013) Morin hydrate: botanical origin, pharmacological activity and its applications: a mini-review. Pharmacogn J 5:123–126. https://doi.org/10.1016/j.phcgj.2013.04.006 CrossRef

20.

Chung SS, Oliva B, Dwabe S, Vadgama JV (2016) Combination treatment with flavonoid morin and telomerase inhibitor MST-312 reduces cancer stem cell traits by targeting STAT3 and telomerase. Int J Oncol 49:487–498. https://doi.org/10.3892/ijo.2016.3546 CrossRefPubMedPubMedCentral

21.

Li B, Jin X, Meng H et al (2017) Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis. Oncotarget 8:47849–47860. https://doi.org/10.18632/oncotarget.18133 CrossRefPubMedPubMedCentral

22.

Chou TC (2010) Drug combination studies and their synergy quantification using the Chou–Talalay method. Cancer Res 70:440–446. https://doi.org/10.1158/0008-5472.CAN-09-1947 CrossRefPubMed

23.

Bijnsdorp IV, Giovannetti E, Peters GJ (2011) Analysis of drug interactions. Methods Mol Biol 731:421–434. https://doi.org/10.1007/978-1-61779-080-5 CrossRefPubMed

24.

Nessa MU, Beale P, Chan C et al (2011) Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models. Anticancer Res 31:3789–3797PubMed

25.

Hossein G, Keshavarz M, Ahmadi S, Naderi N (2013) Synergistic effects of PectaSol-C modified citrus pectin an inhibitor of galectin-3 and paclitaxel on apoptosis of human SKOV-3 ovarian cancer cells. Asian Pac J Cancer Prev 14:7561–7568. https://doi.org/10.7314/APJCP.2013.14.12.7561 CrossRefPubMed

26.

Mazumder MEH, Beale P, Chan C et al (2012) Epigallocatechin gallate acts synergistically in combination with cisplatin and designed trans-palladiums in ovarian cancer cells. Anticancer Res 32:4851–4860PubMed

27.

Chan MM, Fong D, Soprano KJ, Holmes WF (2002) Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J Cell Physiol. https://doi.org/10.1002/jcp.10186 CrossRef

28.

Su Y-K, Huang W-C, Lee W-H et al (2017) Methoxyphenyl chalcone sensitizes aggressive epithelial cancer to cisplatin through apoptosis induction and cancer stem cell eradication. Tumour Biol. https://doi.org/10.1177/1010428317691689 CrossRefPubMed

29.

Lim W, Jeong W, Song G (2016) Delphinidin suppresses proliferation and migration of human ovarian clear cell carcinoma cells through blocking AKT and ERK1/2 MAPK signaling pathways. Mol Cell Endocrinol 422:172–181. https://doi.org/10.1016/j.mce.2015.12.013 CrossRefPubMed

30.

Luo H, Daddysman MK, Rankin GO et al (2010) Kaempferol enhances cisplatin’s effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc. Cancer Cell Int 10:16. https://doi.org/10.1186/1475-2867-10-16 CrossRefPubMedPubMedCentral

31.

Maciejczyk A, Surowiak P (2013) Quercetin inhibits proliferation and increases sensitivity of ovarian cancer cells to cisplatin and paclitaxel. Ginekol Pol 84:590–595CrossRef

32.

Hyun HB, Lee WS, Go SI et al (2015) The flavonoid morin from Moraceae induces apoptosis by modulation of Bcl-2 family members and Fas receptor in HCT 116 cells. Int J Oncol 46:2670–2678. https://doi.org/10.3892/ijo.2015.2967 CrossRefPubMed

33.

Jin H, Lee WS, Eun SY et al (2014) Morin, a flavonoid from Moraceae, suppresses growth and invasion of the highly metastatic breast cancer cell line MDA-MB-231 partly through suppression of the Akt pathway. Int J Oncol 45:1629–1637. https://doi.org/10.3892/ijo.2014.2535 CrossRefPubMed

34.

Ikegawa T, Ohtani H, Koyabu N et al (2002) Inhibition of P-glycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Lett 177:89–93. https://doi.org/10.1016/S0304-3835(01)00761-3 CrossRefPubMed

35.

Li Z, Yang Z, Lapidus RG et al (2015) IKK phosphorylation of NF-κB at serine 536 contributes to acquired cisplatin resistance in head and neck squamous cell cancer. Am J Cancer Res 5:3098–3110PubMedPubMedCentral

36.

Son D-S, Kabir SM, Dong Y et al (2013) Characteristics of chemokine signatures elicited by EGF and TNF in ovarian cancer cells. J Inflamm 10:25. https://doi.org/10.1186/1476-9255-10-25 CrossRef

37.

Kv A, Madhana RM, Kasala ER et al (2016) Morin hydrate mitigates cisplatin-induced renal and hepatic injury by impeding oxidative/nitrosative stress and inflammation in mice. J Biochem Mol Toxicol 30:571–579. https://doi.org/10.1002/jbt.21817 CrossRef

38.

Kaltalioglu K, Coskun-Cevher S (2016) Potential of morin and hesperidin in the prevention of cisplatin-induced nephrotoxicity. Ren Fail 38:1291–1299. https://doi.org/10.1080/0886022X.2016.1209383 CrossRefPubMed

39.

Samuel P, Pink RC, Brooks SA, Carter DR (2016) MiRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance. Expert Rev Anticancer Ther 16:57–70. https://doi.org/10.1586/14737140.2016.1121107 CrossRefPubMed

40.

Lavra L, Ulivieri A, Rinaldo C et al (2009) Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. J Pathol 218:66–75. https://doi.org/10.1002/path CrossRefPubMed

41.

Wang Y, Nangia-Makker P, Balan V et al (2010) Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. Cell Death Dis 1:e101–e110. https://doi.org/10.1038/cddis.2010.79 CrossRefPubMedPubMedCentral

42.

Tseng PC, Chen CL, Shan YS, Lin CF (2016) An increase in galectin-3 causes cellular unresponsiveness to IFN-γ-induced signal transduction and growth inhibition in gastric cancer cells. Oncotarget 7:15150–15160. https://doi.org/10.18632/oncotarget.7750 CrossRefPubMedPubMedCentral

43.

Cheng YL, Huang WC, Chen CL et al (2011) Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli. Biochem Biophys Res Commun 412:334–340. https://doi.org/10.1016/j.bbrc.2011.07.099 CrossRefPubMed

44.

Manna SK, Aggarwal RS, Sethi G et al (2007) Morin (3,5,7,2′,4′ pentahydroxyflavone) abolishes nuclear factor-κB activation induced by various carcinogens and inflammatory stimuli, leading to suppression of nuclear factor-κB regulated gene expression and up regulation of apoptosis. Clin Cancer Res 13:2290–2297. https://doi.org/10.1158/1078-0432.CCR-06-2394.Morin CrossRefPubMedPubMedCentral

45.

Dhanasekar C, Kalaiselvan S, Rasool M (2015) Morin, a bioflavonoid suppresses monosodium urate crystal-induced inflammatory immune response in RAW 264.7 macrophages through the inhibition of inflammatory mediators, intracellular ROS levels and NF-κB activation. PLoS ONE. https://doi.org/10.1371/journal.pone.0145093 CrossRefPubMedPubMedCentral

Title: Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
Authors: Dominik Bieg
Daniel Sypniewski
Ewa Nowak
Ilona Bednarek
Publication date: 01-12-2018
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 6/2018
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-018-4912-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

Association between vitamin D deficiency and antepartum and postpartum depression: a systematic review and meta-analysis of longitudinal studies

Is vaginal progesterone treatment associated with the development of gestational diabetes? A retrospective case–control study

Effects of superovulation, in vitro fertilization, and oocyte in vitro maturation on imprinted gene Grb10 in mouse blastocysts

Effect of intrauterine injection of human chorionic gonadotropin before fresh embryo transfer on IVF and ICSI outcomes: a meta-analysis

Validation of a quantitative system for real-time measurement of postpartum blood loss

Influence of preadipocyte-conditioned medium on the proliferation and invasive potential of breast cancer cell lines in vitro